siRNA News and Research

RSS

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA molecules, 20-25 nucleotides in length, that play a variety of roles in biology. Most notably, siRNA is involved in the RNA interference (RNAi) pathway, where it interferes with the expression of a specific gene. In addition to their role in the RNAi pathway, siRNAs also act in RNAi-related pathways, e.g., as an antiviral mechanism or in shaping the chromatin structure of a genome; the complexity of these pathways is only now being elucidated.

From Our Bench to Yours: Antibody Advice from Proteintech

An interview with Dr. Karolina Szczesna, discussing the tell-tale signs of a good antibody and how Proteintech are working to improve experimental results for scientists.

From Proteintech Group, Inc 5 Dec 2018

RNAi therapy shown to alleviate preeclampsia in animal model

Researcher have used a small interfering RNA (siRNA) to reduce preeclampsia symptoms in an animal model. The approach could provide a new way of treating preeclampsia in humans.

19 Nov 2018

Combination therapy enhances wound healing

By incorporating a gene-suppressing drug into an over-the-counter gel, researchers at Albert Einstein College of Medicine and their colleagues cut healing time by half and significantly improved healing outcomes compared to control treatments.

25 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).

3 Oct 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Antioxidant in green tea helps sneak therapeutic RNAs into cells

Drinking green tea has been linked to health benefits ranging from cardiovascular disease prevention to weight loss.

19 Sep 2018

Researchers describe novel mechanism that links epigenetic change to translational control

Understanding how memories form and are retrieved has applications to psychiatric, neurological and neurodegenerative disorders, and may be helpful to attenuate maladaptive memories in psychiatric disorders.

7 Sep 2018

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

30 Aug 2018

Researchers describe link between poor oocyte development and oxidative stress in obese mice

Excessive body fat is associated with negative effects on female fertility and pregnancy. In mice, maternal obesity impairs proper development of egg precursor cells called oocytes.

17 Aug 2018

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.

10 Aug 2018

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion recommending marketing authorization of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy.

27 Jul 2018

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.

8 Jun 2018

Alnylam achieves delivery of novel siRNAs conjugates to the central nervous system

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the Company has achieved delivery of novel small interfering RNA conjugates to the central nervous system and is planning to advance a pipeline of investigational RNAi therapeutics into clinical development.

8 May 2018

Scientists discover a small family of proteins that control inclusion of DNA methylation marks in genome

Not all of your genome needs to be active at any given time. Some regions are prone to hopping around the genome in problematic ways if left unchecked; others code for genes that need to be turned off in certain cells or at certain times.

8 May 2018

Sylentis presents clinical study results of new treatment for dry eye syndrome

Sylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and that has enabled the start-up of the Phase III "Helix" clinical trial.

3 May 2018

Novel cell-based screening array reduces time and cost of drug discovery

Porvair Sciences has collaborated with Persomics Inc. to develop and supply ANSI/SLAS format Arrays as an OEM product for their ImagineArray™ platform.

From Porvair Sciences Limited 28 Apr 2018

Newly designed three-part molecule shows promise to treat breast cancers

A newly designed three-part molecule could be the one answer patients with a certain form of breast cancer are looking for, scientists report.

22 Mar 2018

New study shows advantages of DNA barcoding technique for identifying nanoparticles

The first direct comparison of in vitro and in vivo screening techniques for identifying nanoparticles that may be used to transport therapeutic molecules into cells shows that testing in lab dishes isn't much help in predicting which nanoparticles will successfully enter the cells of living animals.

5 Mar 2018

siRNA News and Research

From Our Bench to Yours: Antibody Advice from Proteintech

RNAi therapy shown to alleviate preeclampsia in animal model

Combination therapy enhances wound healing

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Antioxidant in green tea helps sneak therapeutic RNAs into cells

Researchers describe novel mechanism that links epigenetic change to translational control

EC grants marketing authorization for ONPATTRO (patisiran) in Europe

Researchers describe link between poor oocyte development and oxidative stress in obese mice

FDA approves first targeted RNA-based treatment for rare, fatal genetic disease

Alnylam’s patisiran receives positive opinion from CHMP for treating hATTR amyloidosis

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam achieves delivery of novel siRNAs conjugates to the central nervous system

Scientists discover a small family of proteins that control inclusion of DNA methylation marks in genome

Sylentis presents clinical study results of new treatment for dry eye syndrome

Novel cell-based screening array reduces time and cost of drug discovery

Newly designed three-part molecule shows promise to treat breast cancers

New study shows advantages of DNA barcoding technique for identifying nanoparticles

Overcoming Challenges in High-Speed Centrifugation Experiments

From Our Bench to Yours: Antibody Advice from Proteintech

Customizing Genetically Engineered Models for Specific Research Applications

Latest News